Insmed Incorporated INSM 深 滬
已收盤 02-06 16:00:00 美东时间
149.86
-1.170
-0.77%
華盛通- 最 高155.79
- 今 開153.06
- 成交量 262.97万股
- 最 低 149.34
- 昨 收 151.03
- 總市值 319.61亿
- 52周最高 212.75
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 60.40
- 委 比 93.90%
- 總股本 2.13亿
- 歷史最高 212.75
- 量 比 1.15
- 振 幅 4.27%
- 歷史最低 2.64
- 每 手 1
- 風險率 45.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On Insmed with Overweight Rating, Announces Price Target of $231
Barclays analyst Eliana Merle initiates coverage on Insmed (NASDAQ:INSM) with a Overweight rating and announces Price Target of $231.
01-28 22:39
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Insmed a new buy at Roth on Brinsupri and Arikayce sales
Roth has initiated Insmed (INSM) at buy saying it sees above consensus sales of Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension). The firm set a $212 price target (~32% ...
01-23 23:29
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Breaking Down Insmed: 18 Analysts Share Their Views
During the last three months, 18 analysts shared their evaluations of Insmed (N...
01-22 02:01
RBC Capital Maintains Outperform on Insmed, Raises Price Target to $200
RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $197 to $200.
01-21 22:25
美股盘后 | Revvity, Inc.涨5.88%，Insmed Incorporated涨5.47%
Revvity, Inc.涨5.88%；Insmed Incorporated涨5.47%；美洲移动涨3.30%
01-13 07:10
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical milestones across its pipeline.
01-09 23:58
